Technical Analysis for SLRX - Salarius Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.49 | 2.35% | 0.01 |
SLRX closed up 2.35 percent on Wednesday, May 8, 2024, on 9 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
20 DMA Resistance | Bearish | 2.35% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 2.35% | |
Bollinger Band Squeeze | Range Contraction | 2.35% | |
BB Squeeze + Lower Band Touch | Range Contraction | 2.35% | |
Gapped Up | Strength | 2.35% | |
Down 3 Days in a Row | Weakness | 2.35% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 11 hours ago |
60 Minute Opening Range Breakout | about 13 hours ago |
Up 2% | about 13 hours ago |
Up 1% | about 13 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Clinical Development Oncology Breast Cancer Prostate Cancer Ovarian Cancer Treatment Of Breast Cancer Sarcoma Advanced Solid Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Clinical Development Oncology Breast Cancer Prostate Cancer Ovarian Cancer Treatment Of Breast Cancer Sarcoma Advanced Solid Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.8694 |
52 Week Low | 0.43 |
Average Volume | 135,974 |
200-Day Moving Average | 0.67 |
50-Day Moving Average | 0.55 |
20-Day Moving Average | 0.50 |
10-Day Moving Average | 0.50 |
Average True Range | 0.05 |
RSI (14) | 45.05 |
ADX | 29.54 |
+DI | 13.82 |
-DI | 10.59 |
Chandelier Exit (Long, 3 ATRs) | 0.42 |
Chandelier Exit (Short, 3 ATRs) | 0.60 |
Upper Bollinger Bands | 0.53 |
Lower Bollinger Band | 0.47 |
Percent B (%b) | 0.29 |
BandWidth | 11.54 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0013 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.51 | ||||
Resistance 3 (R3) | 0.51 | 0.50 | 0.51 | ||
Resistance 2 (R2) | 0.50 | 0.49 | 0.50 | 0.50 | |
Resistance 1 (R1) | 0.49 | 0.49 | 0.49 | 0.49 | 0.50 |
Pivot Point | 0.48 | 0.48 | 0.48 | 0.48 | 0.48 |
Support 1 (S1) | 0.48 | 0.48 | 0.48 | 0.48 | 0.47 |
Support 2 (S2) | 0.47 | 0.47 | 0.47 | 0.47 | |
Support 3 (S3) | 0.46 | 0.47 | 0.47 | ||
Support 4 (S4) | 0.46 |